SCHEMBL31010092

SCHEMBL31010092

CC(C)(C)OC(=O)N1CCC[C@H](n2nc(Br)c(Br)n2)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 2/20 0.48
HPGD P15428 1/20 0.47
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPT P10636 1/20 0.46
KMT2A Q03164 1/20 0.46
HCAR1 Q9BXC0 1/20 0.42
PIK3CD O00329 1/20 0.41
PIK3R2 O00459 1/20 0.41
PIK3CA P42336 1/20 0.41
PIK3CB P42338 1/20 0.41
PIK3CG P48736 1/20 0.41
PIK3R5 Q8WYR1 1/20 0.41
PIK3R3 Q92569 1/20 0.41
CHRNA7 P36544 1/20 0.41
GLS O94925 1/20 0.41
PREP P48147 1/20 0.40
USP30 Q70CQ3 1/20 0.40
HPGDS O60760 1/20 0.40
HDAC4 P56524 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31340305 1.00 FPR2 (0.48) FPR2HPGDMEN1ALDH1A1MAPT
SCHEMBL31340230 0.87 FPR2 (0.46) FPR2HPGDMEN1ALDH1A1MAPT
SCHEMBL29341768 0.87 FPR2 (0.46) FPR2HPGDMEN1ALDH1A1MAPT
SCHEMBL16716853 0.83 HPGD (0.51) FPR2HPGDMAPTKMT2ARECQL
SCHEMBL29806095 0.81 MEN1 (0.48) FPR2HPGDMEN1ALDH1A1MAPT
SCHEMBL30318605 0.79 FPR2 (0.44) FPR2HPGDMEN1ALDH1A1MAPT
SCHEMBL30318669 0.79 FPR2 (0.44) FPR2HPGDMEN1ALDH1A1MAPT
SCHEMBL31437951 0.79 FPR2 (0.46) FPR2HPGDMEN1ALDH1A1MAPT
SCHEMBL24672638 0.77 MEN1 (0.52) FPR2HPGDMEN1ALDH1A1MAPT
SCHEMBL7388998 0.77 HPGD (0.54) FPR2HPGDMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4648763-A2 COMPOUNDS FOR FGFRS INHIBITORS Cogent Biosciences, Inc. (US) 2025-11-19 EP disclosed
US-20240270741-A1 COMPOUNDS FOR FGFRS INHIBITORS COGENT BIOSCIENCES, INC. 2024-08-15 US disclosed
WO-2024151638-A2 COMPOUNDS FOR FGFRS INHIBITORS COGENT BIOSCIENCES, INC. (US) 2024-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240270741-A1 COMPOUNDS FOR FGFRS INHIBITORS FGFR1, FGFR3, FGFR2 FPR2 2207/4885HPGD 4566/4885MEN1 2062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.